Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy (Q64086803)

From Wikidata

Jump to navigation Jump to search

scientific article published on 02 April 2019

Language	Label	Description	Also known as
English	Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy	scientific article published on 02 April 2019

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy (English)

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Francesca Consoli

1

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

author name string

Ausilia Maria Manganoni

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

Salvatore Grisanti

3

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

Fausto Petrelli

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

Marina Venturini

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

Giovanni Rangoni

6

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

Francesco Guarneri

7

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

Paolo Incardona

8

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

William Vermi

9

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

Pier Giacomo Calzavara Pinton

10

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

Alfredo Berruti

11

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

language of work or name

0 references

publication date

2 April 2019

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

14

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

e0214884

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

copyright license

Creative Commons Attribution 4.0 International

2 April 2019

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Melanoma of unknown primary with nodal metastases, presenting with vitiligo-like depigmentation

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Can Vemurafenib Induce Vitiligo in Metastatic Melanoma Patients?

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vitiligo of the Face in a Patient Treated With Vemurafenib for Metastatic Melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cutaneous Complications of Targeted Melanoma Therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunological effects of BRAF MEK inhibition

1 reference

https://pubmed.ncbi.nlm.nih.gov/30939167

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0214884

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30939167 AND SRC:MED&resulttype=core&format=json

1 May 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q64086803&oldid=2241541168"